Literature DB >> 8396727

Differential signal transduction by five splice variants of the PACAP receptor.

D Spengler1, C Waeber, C Pantaloni, F Holsboer, J Bockaert, P H Seeburg, L Journot.   

Abstract

The two forms of pituitary adenylyl cyclase-activating polypeptide (PACAP-27 and -38) are neuropeptides of the secretin/glucagon/vasoactive intestinal polypeptide/growth-hormone-releasing hormone family and regulate hormone release from the pituitary and adrenal gland. They may also be involved in spermatogenesis, and PACAP-38 potently stimulates neuritogenesis and survival of cultured rat sympathetic neuroblast and promotes neurite outgrowth of PC-12 cells. The PACAP type-I receptor (found in hypothalamus, brain stem, pituitary, adrenal gland and testes), specific for PACAP, is positively coupled to adenylyl cyclase and phospholipase C. The recently cloned type II receptor does not discriminate between PACAP and vasoactive intestinal polypeptide and is coupled to only adenylyl cyclase. Here we have used a new expression cloning strategy, based on the induction of a reporter gene by cyclic AMP, to isolate a complementary DNA encoding the type-I PACAP receptor. On transfection of this cDNA, both PACAP-27 and -38 stimulate adenylyl cyclase with similar EC50 values (50% effective concentration, 0.1-0.4 nM), whereas only PACAP-38 stimulates phospholipase C with high potency (EC50 = 15 nM). Four other splice variants were isolated with insertions at the C-terminal end of the third intracellular loop. Expression of these cDNAs revealed altered patterns of adenylyl cyclase and phospholipase C stimulation, suggesting a novel mechanism for fine tuning of signal transduction.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8396727     DOI: 10.1038/365170a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  226 in total

1.  Constitutively active mutants of 5-HT4 receptors are they in unique active states?

Authors:  S Claeysen; M Sebben; C Bécamel; M L Parmentier; A Dumuis; J Bockaert
Journal:  EMBO Rep       Date:  2001-01       Impact factor: 8.807

2.  Isolation of the serotoninergic 5-HT4(e) receptor from human heart and comparative analysis of its pharmacological profile in C6-glial and CHO cell lines.

Authors:  J Mialet; I Berque-Bestel; P Eftekhari; M Gastineau; M Giner; Y Dahmoune; P Donzeau-Gouge; J Hoebeke; M Langlois; S Sicsic; R Fischmeister; F Lezoualc'h
Journal:  Br J Pharmacol       Date:  2000-02       Impact factor: 8.739

3.  G(q/11) and G(i/o) activation profiles in CHO cells expressing human muscarinic acetylcholine receptors: dependence on agonist as well as receptor-subtype.

Authors:  E C Akam; R A Challiss; S R Nahorski
Journal:  Br J Pharmacol       Date:  2001-02       Impact factor: 8.739

4.  Pituitary adenylate cyclase-activating polypeptide may function as a neuromodulator in guinea-pig adrenal medulla.

Authors:  M Inoue; N Fujishiro; K Ogawa; M Muroi; Y Sakamoto; I Imanaga; S Shioda
Journal:  J Physiol       Date:  2000-11-01       Impact factor: 5.182

5.  (N-stearyl, norleucine17)VIPhybrid is a broad spectrum vasoactive intestinal peptide receptor antagonist.

Authors:  Terry W Moody; Robert T Jensen; Mati Fridkin; Illana Gozes
Journal:  J Mol Neurosci       Date:  2002 Feb-Apr       Impact factor: 3.444

6.  Dissociation between light-induced phase shift of the circadian rhythm and clock gene expression in mice lacking the pituitary adenylate cyclase activating polypeptide type 1 receptor.

Authors:  J Hannibal; F Jamen; H S Nielsen; L Journot; P Brabet; J Fahrenkrug
Journal:  J Neurosci       Date:  2001-07-01       Impact factor: 6.167

7.  Pituitary adenylyl cyclase-activating polypeptide stimulates DNA synthesis but delays maturation of oligodendrocyte progenitors.

Authors:  M Lee; V Lelievre; P Zhao; M Torres; W Rodriguez; J Y Byun; S Doshi; Y Ioffe; G Gupta; A E de los Monteros; J de Vellis; J Waschek
Journal:  J Neurosci       Date:  2001-06-01       Impact factor: 6.167

8.  Constitutive activation of tethered-peptide/corticotropin-releasing factor receptor chimeras.

Authors:  S M Nielsen; L Z Nielsen; S A Hjorth; M H Perrin; W W Vale
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-29       Impact factor: 11.205

9.  Domains determining agonist selectivity in chimaeric VIP2 (VPAC2)/PACAP (PAC1) receptors.

Authors:  E M Lutz; C J MacKenzie; M Johnson; K West; J A Morrow; A J Harmar; R Mitchell
Journal:  Br J Pharmacol       Date:  1999-10       Impact factor: 8.739

Review 10.  PACAP signaling to DREAM: a cAMP-dependent pathway that regulates cortical astrogliogenesis.

Authors:  Mario Vallejo
Journal:  Mol Neurobiol       Date:  2009-02-24       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.